scholarly journals Heterologous Immune Responses to Influenza Vaccine in Kidney Transplant Recipients

2016 ◽  
Vol 17 (1) ◽  
pp. 281-286 ◽  
Author(s):  
D. Kumar ◽  
V. H. Ferreira ◽  
P. Campbell ◽  
K. Hoschler ◽  
A. Humar
Keyword(s):  
Immune Responses ◽  
Influenza Vaccine ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Impact of Anti–T-Cell Therapy in the Immunogenicity of Seasonal Influenza Vaccine in Kidney Transplant Recipients

2012 ◽  
Vol 94 (6) ◽  
pp. 630-636 ◽  
Author(s):  
Angela Orcurto ◽  
Manuel Pascual ◽  
Katja Hoschler ◽  
Vincent Aubert ◽  
Pascal Meylan ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Influenza Vaccine ◽  
Kidney Transplant ◽  
Seasonal Influenza ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
T Cell Therapy ◽  
Seasonal Influenza Vaccine

scholarly journals Impaired immune response to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients

Kidney360 ◽  
2021 ◽  
pp. 10.34067/KID.0003512021
Author(s):  
Thilo Kolb ◽  
Svenja Fischer ◽  
Lisa Müller ◽  
Nadine Lübke ◽  
Jonas Hillebrandt ◽  
...  
Keyword(s):  
Immune Responses ◽  
Kidney Transplant ◽  
Kidney Failure ◽  
Neutralizing Antibodies ◽  
Neutralizing Antibody ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Dialysis Patients ◽  
Specific Antibodies ◽  
Neutralization Capacity

Background: Kidney failure patients on dialysis or after renal transplantation have a high risk for severe COVID-19 infection and vaccination against SARS-CoV-2 is the only expedient prophylaxis. Generally, immune responses are attenuated in kidney failure patients, however, systematic analyses of immune responses to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients (KTR) are still missing. Methods: In this prospective multicentric cohort study, antibody responses COVID-19 mRNA vaccines (BNT162b2; Biontech/Pfizer or mRNA-1273; Moderna) were measured in 32 dialysis patients and in 28 KTRs. SARS-CoV-2-specific antibodies and neutralization capacity were evaluated and compared to controls (n=78) in a similar age-range. Results: After the first vaccination, SARS-CoV-2-specific antibodies were nearly undetectable in kidney failure patients. After the second vaccination, 93% of the controls and 88% of dialysis patients but only 37% of KTRs developed SARS-CoV-2-specific IgG above cut-off. Moreover, mean IgG levels were significantly lower in KTRs (54±93 BAU/ml) compared to dialysis patients (503±481 BAU/ml, p<0.01). Both KTRs as well as dialysis patients had significantly lower IgG levels compared to controls (1992±2485 BAU/ml; p<0.001 and p<0.01). Importantly, compared to controls, neutralizing antibody titers were significantly lower in KTRs and dialysis patients. After the second vaccination, 76% of KTRs did not show any neutralization capacity against SARS-CoV-2 suggesting impaired seroprotection. Conclusions: Kidney failure patients show a significantly weaker antibody response compared to controls. Most strikingly, only one out four KTRs developed neutralizing antibodies against SARS-CoV-2 after two doses of vaccine. These data suggest that vaccination strategies need modification in immune transplant and dialysis patients.

scholarly journals 638. CMV-Specific T-Cell Immune Responses in Older vs. Younger Kidney Transplant Recipients

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S232-S232
Author(s):  
Emily Liang ◽  
Maura Rossetti ◽  
Gemalene Sunga ◽  
Elaine Reed ◽  
Joanna Schaenman
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
T Cell Immune Responses

Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients

2016 ◽  
Vol 100 (3) ◽  
pp. 662-669 ◽  
Author(s):  
Deepali Kumar ◽  
Patricia Campbell ◽  
Katja Hoschler ◽  
Luis Hidalgo ◽  
Mona Al-Dabbagh ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Influenza Vaccine ◽  
Kidney Transplant ◽  
Controlled Trial ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Randomized Controlled

Dissociation of humoral and cellular immune responses in kidney transplant recipients with EBV mucocutaneous ulcer

2021 ◽  
Author(s):  
Pierre Isnard ◽  
Julie Bruneau ◽  
Rebecca Sberro‐Soussan ◽  
Dominique Wendum ◽  
Christophe Legendre ◽  
...  
Keyword(s):  
Immune Responses ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cellular Immune Responses ◽  
Cellular Immune

scholarly journals Six-Month Follow-Up after Vaccination with BNT162b2: SARS-CoV-2 Antigen-Specific Cellular and Humoral Immune Responses in Hemodialysis Patients and Kidney Transplant Recipients

Pathogens ◽  
2022 ◽  
Vol 11 (1) ◽  
pp. 67
Author(s):  
Simone Cosima Boedecker-Lips ◽  
Anja Lautem ◽  
Stefan Runkel ◽  
Pascal Klimpke ◽  
Daniel Kraus ◽  
...  
Keyword(s):  
Immune Responses ◽  
Kidney Transplant ◽  
Cell Response ◽  
Cellular Response ◽  
Chronically Ill ◽  
Response Rates ◽  
Hemodialysis Patients ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Antibody Titers

Hemodialysis patients (HDP) and kidney transplant recipients (KTR) have a high risk of infection with SARS-CoV-2 with poor clinical outcomes. Because of this, vaccination of these groups of patients against SARS-CoV-2 is particularly important. However, immune responses may be impaired in immunosuppressed and chronically ill patients. Here, our aim was to compare the efficacy of an mRNA-based vaccine in HDP, KTR, and healthy subjects. Design: In this prospective observational cohort study, the humoral and cellular response of prevalent 192 HDP, 50 KTR, and 28 healthy controls (HC) was assessed 1, 2, and 6 months after the first immunization with the BNT162b2 mRNA vaccine. Results: After 6 months, 97.5% of HDP, 37.9% of KTR, and 100% of HC had an antibody response. Median antibody levels were 1539.7 (±3355.8), 178.5 (±369.5), and 2657.8 (±2965.8) AU/mL in HDP, KTR, and HC, respectively (p ≤ 0.05). A SARS-CoV-2 antigen-specific cell response to vaccination was found in 68.8% of HDP, 64.5% of KTR, and 90% of HC. Conclusion: The humoral response rates to mRNA-based vaccination of HDPs are comparable to HCs, but antibody titers are lower. Furthermore, HDPs have weaker T-cell response to vaccination than HCs. KTRs have very low humoral and antigen-specific cellular response rates and antibody titers, which requires other vaccination strategies in addition to booster vaccination.

Sign in / Sign up

Export Citation Format

Share Document